This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1076029609335501v1 1076029609335501v2 15/6/636    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Monien, S. Articles by Kiesewetter, H. PubMed PubMed Citation Articles by Monien, S. Articles by Kiesewetter, H. Social Bookmarking                         What's this?

Use of Heparin in Women With Early and Late Miscarriages With and Without Thrombophilia

^* To whom correspondence should be addressed. E-mail: silke.monien{at}charite.de.

	Abstract

Objective: In women with a history of recurrent miscarriage, the risk of miscarriage in a subsequent pregnancy is about 30% to 40%. In patients with thrombophilia, the risk is even higher. Placental thrombosis has been found in women with unexplained recurrent miscarriage independent of thrombophilia. In addition, proinflammatory changes, for example, altered Th1 to Th2 cytokine ratio and complement activation, have been repeatedly demonstrated in these women. Because of the fact that heparin has both anticoagulative and anti-inflammatory effects, the current study evaluated the efficacy of low-molecular-weight heparin (LMWH) in unexplained abortions. Study Design: A total of 164 women with unexplained early and late miscarriages presented in our hemostaseological clinic for thrombophilia screening. For these 164 women, 82 subsequent pregnancies in 79 patients were treated with subcutaneous LMWH independently of thrombophilia. In 54/82 unselected pregnancies, 100 mg aspirin was administered in addition to LMWH. Two patients were excluded due to termination of pregnancy. Results: Overall, 83.8% (67/80) of pregnancies resulted in live births. In 22/79 women (27.8%), thrombophilia markers were positive. Most noteworthy, patients with thrombophilia markers had live births at a similar frequency as patients without those parameters. No severe side effects of LMWH were seen. Conclusions: Our data support the notion that LMWH is efficacious in patients with recurrent abortions and thrombophilia. We demonstrated the same effect of LMWH in women with unexplained abortions without thrombophilia. The potential mechanism of action of LMWH in early and late abortions warrants further study.

First published on August 9, 2009, doi:10.1177/1076029609335501

Clinical and Applied Thrombosis/Hemostasis 2009;15:636.

A more recent version of this article appeared on December 1, 2009
This version was published on October 14, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?